C12N 2730/10023
Virus like particles [vlp]
Official title: Virus like particles [VLP]
C12N2730/10023 (Virus like particles [vlp]) appears on 8 US grants and 11 published applications in this corpus.
Search patents in C12N- Granted patents
- 8
- Published applications
- 11
- Assignees
- 10
- Inventors
- 21
- Latest grant
- 2 Apr 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 1 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 1 | 0 |
| 2011 | 1 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 0 | 1 |
| 2019 | 1 | 0 |
| 2020 | 0 | 2 |
| 2021 | 2 | 0 |
| 2022 | 1 | 2 |
| 2023 | 0 | 0 |
| 2024 | 1 | 1 |
| 2025 | 0 | 1 |
By publication year.
Recent patents
- Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses2 Apr 2024US 11,944,677 B2Verimmune Inc.
- Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses29 Mar 2022US 11,285,203 B2Verimmune Inc.
- Vaccines against Zika virus based on Zika structure proteins3 Aug 2021US 11,078,491 B2Arizona Board of Regents on behalf of Arizona State University
- Method for separating virus-like particles from a cell suspension6 Jul 2021US 11,053,478 B2Artes Biotechnology GmbH
- Rodent hepadnavirus cores with reduced carrier-specific antigenicity28 May 2019US 10,300,124 B2VLP Biotech, Inc.
- Immunogens targeting anthrax15 May 2025US 2025/0152692 A1The Regents of the University of Michigan
- Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses28 Nov 2024US 2024/0390473 A1Verimmune Inc.
- Hybrid virus-like particles and use thereof as a therapeutic hepatitis b vaccine29 Dec 2022US 2022/0411475 A1VLP Biotech, Inc.
- Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses21 Jul 2022US 2022/0226460 A1Verimmune Inc.
- Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses16 Apr 2020US 2020/0113996 A1Pathovax LLC
Most cited
By later US patents
- Hepadnavirus cores9US 6,518,014 B1Bristol-Myers Squibb Company · 2003
- Hepatitis virus core proteins as vaccine platforms and methods of use thereof8US 7,883,843 B2Vaccine Research Institute of San Diego · 2011
- Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses2US 11,285,203 B2Verimmune Inc. · 2022
- Rodent hepadnavirus cores with reduced carrier-specific antigenicity1US 10,300,124 B2VLP Biotech, Inc. · 2019